SCOTTSDALE, Ariz.—Could intrathecal therapy be a solution for patients with peripheral neuropathy who have failed all other treatments? A case report and literature search on its appropriateness for neuropathy-induced refractory pain have validated the decision to proceed with the therapy, according to a poster at the 2022 annual meeting of the American Academy of Pain Medicine.
“The 37-year-old male has been seen at my clinic at the VA Hospital in Tampa since last October,”